About Medexus Pharmaceuticals, Inc. 
Medexus Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc, is a Canada-based company engaged in pharmaceutical business sector. The Company is a North American focused, specialty pharmaceutical business that operates through three segments: Medac Pharma USA, a fully integrated commercial infrastructure focused on auto-immune diseases in the United States; Medexus Pharma Canada, a fully integrated commercial infrastructure focused on auto-immune disease and pediatric diseases in Canada; and a Business Development function, which works to maintain its product pipeline. The Company's flag products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an allergy medication. The Company provides products for the healthcare professionals and patients.
Company Coordinates 
Company Details
225-1 du Commerce Pl , VERDUN QC : H3E 1A2
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. Peter Van der Velden
Independent Chairman of the Board
Mr. Kenneth D'Entremont
Chief Executive Officer, Director
Mr. Benoit Gravel
Independent Director
Ms. Adele Gulfo
Independent Director
Mr. Michael Mueller
Independent Director
Mr. Stephen Nelson
Independent Director
Revenue and Profits:
Net Sales:
34 Million
(Quarterly Results - Jun 2025)
Net Profit:
1 Million
Pharmaceuticals & Biotechnology
CAD 92 Million (Micro Cap)
20.00
NA
0.00%
0.24
6.27%
1.28






